Archive: Established and Emerging Prognostic Markers in Prostate Pathology
Prostate cancer makes up 1 in 5 new cancer diagnoses in men. In the United States, there is estimated to be over 260,000 new prostate cancer cases and 34,500 deaths due to this disease in the last year. While the early detection of prostate cancer remains an important step in preventing cancer related deaths, many patients diagnosed with prostate cancer will die of other causes. Thus, it is equally important to determine the biologic potential of an individual’s tumor. New techniques such as multiparametric MRI of the prostate and MRI-targeted biopsy have improved the detection and diagnosis of clinically significant prostate cancer. At the same time, new recommendations in the reporting of prostate cancer grade, morphology, and other histologic findings on prostate biopsy have helped guide clinicians in terms of choosing active surveillance versus recommending definitive therapy. This presentation addresses recent advances in the detection of prostate cancer and recommendations for the reporting of established and emerging prognostic markers in prostate pathology.
Jennifer Gordetsky, MD
Professor, Medical Director of Anatomic Pathology
Departments of Pathology, Microbiology, and Immunology; Urology
Vanderbilt University Medical Center
01/04/23
The University of Washington is committed to ensuring digital accessibility in our services, programs, and activities. If you encounter accessibility barriers using videos found on this channel, please contact UW Video at [email protected].